European CHMP recommends approval of generic abiraterone acetate (Abiraterone KRKA) for treatment of metastatic prostate cancer

Studies have demonstrated the satisfactory quality of Abiraterone KRKA, and its bioequivalence to the reference originator product Zytiga. It will be licensed for the same indications as Zytiga.

Source:

European Medicines Agency